Document:

Exhibit 10.3

 Exhibit 10.3 
  

Lock-Up Agreement 

January 14, 2015 
 Ladies and
Gentlemen: 
 The undersigned (the “Stockholder”) understands that: (i) Regado Biosciences, Inc., a Delaware
corporation (“Parent”), has entered into an Agreement and Plan of Merger and Reorganization, dated as of January 13, 2015 (the “Merger Agreement”), with Tobira Therapeutics, Inc., a Delaware
corporation (the “Company”), Landmark Merger Sub Inc., a Delaware corporation (“Merger Sub”), and Brent Ahrens as the “Stockholders’ Agent” pursuant to which Merger Sub
will be merged with and into the Company (the “Merger”) and the separate corporate existence of Merger Sub will cease and the Company will continue as the surviving corporation; (ii) in connection with the Merger,
stockholders of the Company will receive shares of Parent Common Stock (the “Merger Shares”); and (iii) certain stockholders of the Company have, pursuant to the Financing Commitment Letter, agreed to purchase additional
shares of Parent Common Stock (the “PIPE Shares”). Capitalized terms used but not otherwise defined in this agreement (this “Lock-Up Agreement”) will have the
meanings ascribed to such terms in the Merger Agreement. 
 As a material inducement to the willingness of each of Parent and the Company
entering into the Merger Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Stockholder agrees that during the period beginning on the date of the Merger Agreement and
continuing until and including the 90 day anniversary of the Closing Date (the “Restricted Period”), the Stockholder (or its successors, assigns or designees) will not, with respect to [    ]% of the
Stockholder’s Shares (as defined below) (A) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or
dispose of, directly or indirectly, any shares of Parent Common Stock (including, for clarity, any Merger Shares or PIPE Shares, as applicable) or any securities convertible into or exercisable or exchangeable for Parent Common Stock, including
without limitation, such other securities of Parent which may be deemed to be beneficially owned by the Stockholder in accordance with the rules and regulations of the Securities and Exchange Commission and securities of Parent which may be issued
upon exercise of a stock option or warrant (collectively, the “Stockholder’s Shares”) or (B) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership
of the Parent Common Stock or such other securities, whether any such transaction described in clause (A) or (B) above is to be settled by delivery of Parent Common Stock or such other securities, in cash or otherwise, in each case other
than (i) transfers or dispositions of the Stockholder’s Shares to a trust, the beneficiaries of which are exclusively the Stockholder and/or a member or members of the Stockholder’s immediate family, (ii) transfers or
dispositions of the Stockholder’s Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the Stockholder, (iii) transfers of the
Stockholder’s Shares as a bona fide gift or gifts, (iv) transfers or dispositions of the Stockholder’s Shares to any corporation, partnership, limited liability company or other entity, all of the beneficial ownership interests of
which are held by the Stockholder or the immediate family of the Stockholder, (v) transfers of the Stockholder’s Shares to partners, members or stockholders of the Stockholder, or to another partnership, limited

 
liability company, corporation or other business entity that is an affiliate (within the meaning set forth in Rule 405 under the Securities Act) of or controls, is controlled by or is under
common control with the Stockholder, (vi) transfers that occur by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement; provided that the applicable recipient(s) agrees in writing to be bound by the
restrictions set forth in this Lock-Up Agreement as if such recipient(s) had been an original party hereto, prior to such transfer, and provided further that any filing required to be made under Section 16(a) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”) shall state that such transfer is pursuant to a qualified domestic order or in connection with a divorce settlement, and (vii) the conversion of any outstanding securities of the
Company into Merger Shares, provided such shares shall be subject to the restrictions set forth herein during the Lock-Up Period. For purposes of this Lock-Up Agreement, “immediate family” means any relationship by blood, marriage or
adoption, not more remote than first cousin. 
 Notwithstanding the restrictions imposed by this Lock-Up Agreement, the Stockholder may
(i) exercise an option (including a net or cashless exercise of an option) to purchase shares of Parent Common Stock, and transfer shares of Parent Common Stock to Parent to cover tax withholding obligations of the Stockholder in connection
with any such option exercise, provided that the underlying shares of Parent Common Stock will continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement, (ii) establish a trading plan pursuant to Rule 10b5-1
under the Exchange Act for the transfer of Parent Common Stock, provided that such plan does not provide for any transfers of Parent Common Stock during the Restricted Period, (iii) perform its obligations (or exercise rights of assignment)
under the Financing Commitment Letter, if applicable, and (iv) transfer or dispose of shares of Parent Common Stock acquired on the open market following the Closing Date; provided that, with respect to each of (i) – (ii) and
(iv) above, no filing under the Exchange Act other public announcement shall be required or shall be made voluntarily in connection with such transfer or disposition during the Restricted Period (other than in respect of a required filing under
the Exchange Act in connection with the exercise of an option to purchase Parent Common Stock following such individual’s termination of employment with the Company that would otherwise expire during the Restricted Period, provided that
reasonable notice shall be provided to the Company prior to any such filing, and provided further that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth
in this letter agreement). 
 An attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void,
regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the stock transfer books of Parent. In order to ensure compliance
with the restrictions referred to herein, the Stockholder agrees that Parent may issue appropriate “stop transfer” certificates or instructions. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to
be placed upon any certificate(s) or other documents or instruments evidencing ownership of the Stockholder’s Shares: 
 THE SHARES
REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. 

 The Stockholder hereby represents and warrants that the Stockholder has full power and authority
to enter into this Lock-Up Agreement. All authority conferred or agreed to be conferred and any obligations of the Stockholder under this Lock-Up Agreement will be binding upon the successors, assigns, heirs or personal representatives of the
Stockholder. 
 In the event that any holder of Parent’s securities that is subject to a substantially similar letter agreement entered
into by such holder, other than the undersigned, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock for value other than as permitted by this or a substantially similar letter agreement entered into by
such holder, the same percentage of shares of Parent Common Stock held by the Stockholder (the “Pro-Rata Release”) shall be immediately and fully released on the same terms from any remaining restrictions set forth herein;
provided, however, that such Pro-Rata Release shall not be applied unless and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise transfer or dispose all or a portion of such equity holders’
shares of Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock originally subject to a substantially similar letter agreement. 

Upon the release of any of the Stockholder’s Shares from this Lock-Up Agreement, Parent will cooperate with the Stockholder to facilitate
the timely preparation and delivery of certificates representing the Stockholder’s Shares without the restrictive legend above or the withdrawal of any stop transfer instructions. 

The Stockholder understands that each of Parent and the Company is relying upon this Lock-Up Agreement in proceeding toward consummation of
the Merger. The Stockholder further understands that this Lock-Up Agreement is irrevocable and is binding upon the Stockholder’s heirs, legal representatives, successors and assigns. 

This Lock-Up Agreement and any claim, controversy or dispute arising under or related to this Lock-Up Agreement will be governed by and
construed in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof. Any action, suit or other Legal Proceeding relating to this Lock-Up Agreement or the enforcement of any provision of this
Lock-Up Agreement will be brought or otherwise commenced exclusively in any state or federal court located in the County of New Castle, State of Delaware. The Stockholder: (i) expressly and irrevocably consents and submits to the exclusive
jurisdiction of each state and federal court located in the County of New Castle, State of Delaware (and each appellate court located in the County of New Castle, State of Delaware) in connection with any such action, suit or Legal Proceeding;
(ii) agrees that each state and federal court located in the County of New Castle, State of Delaware will be deemed to be a convenient forum; and (iii) agrees not to assert (by way of motion, as a defense or otherwise), in any such action,
suit or Legal Proceeding commenced in any state or federal court located in the County of New Castle, State of Delaware, any claim that such party is not subject personally to the jurisdiction of such court, that such action, suit or Legal
Proceeding has been brought in an inconvenient forum, that the venue of such action, suit or other Legal Proceeding is improper or that this Lock-Up Agreement or the subject matter of this Lock-Up Agreement may not be enforced in or by such court.
THE STOCKHOLDER HEREBY IRREVOCABLY WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR OTHER LEGAL PROCEEDING ARISING OUT OF THIS LOCK-UP AGREEMENT. 

 The Stockholder understands that if the Merger Agreement is terminated in accordance with its
terms, the Stockholder will be released from all obligations under this Lock-Up Agreement. 

 This Lock-Up Agreement may be executed by facsimile or electronic (i.e., PDF) transmission, which
is deemed an original. 
  

	
	Very truly yours,
	
	   

	

  
  

	
	Address:
	
	   

	
	   

	
	   

	
	Facsimile No: (        ) -          -Exhibit 10.4

 Exhibit 10.4 
  

 
 January 14, 2015 

 

	To:	Investors listed on Schedule A 

  

	 	Re:	Equity Commitment 

 Ladies and Gentlemen: 

Reference is made to the Agreement and Plan of Merger, dated as of the date hereof (as it may be amended from time to time, the
“Merger Agreement”), by and among Regado Biosciences, Inc., a Delaware corporation (“Parent”), Landmark Merger Sub Inc., a Delaware corporation (“Merger Sub”), Tobira Therapeutics, Inc., a Delaware
corporation (“Company”), and, solely with respect to Section 5.14, Brent Ahrens, as the “Company Stockholders’ Agent”, pursuant to which Merger Sub will merge with and into the Company, with the Company surviving
as the surviving corporation (the “Merger”). Capitalized terms used but not defined herein have the meanings ascribed to them in the Merger Agreement. The parties listed on Schedule A attached hereto are collectively referred
to herein as the “Investors.” This letter agreement is being delivered to Parent in connection with the execution of the Merger Agreement by Parent and the Company. The obligations, covenants, representations and warranties of the
Investors hereunder shall in all respects be several and not joint. 
 This letter agreement confirms the irrevocable commitment of each of
the Investors, subject to the conditions set forth herein, to purchase, or cause an assignee permitted by subpart (a) of the fourth paragraph of this letter agreement to purchase, shares of common stock of Parent, $0.001 par value per share
(“Parent Common Stock”), immediately following the Effective Time for their Pro Rata Percentage (as defined below) of an aggregate purchase price equal to $22,000,000 less (i) Surplus Net Cash (as defined below), if any, less
(ii) the aggregate amount of Additional Company Funding occurring prior to the Effective Time, if any (provided such funding was made in accordance with the terms of this letter agreement), less (iii) any amount assigned by the Company
under subpart (b) of the fourth paragraph hereof (collectively, the “Total Equity Commitment”), provided that the Investors shall not, under any circumstances, be obligated to commit or invest on the aggregate (directly or
indirectly, as applicable) more than the Total Equity Commitment and, provided further, that each Investor shall not, under any circumstances, be obligated to commit or invest on an individual basis more than the amount specified in the column
titled “Maximum Investment” set forth opposite such Investor’s name on Schedule A. Each Investor hereby commits to purchase, or cause to be purchased, that number of shares of Parent Common Stock calculated by taking an amount
equal to (x) its Pro Rata Percentage (as defined below), multiplied by (y) the Total Equity Commitment, divided by (z) in the Parent Stipulated Value. It is understood that the equity investments contemplated hereby will occur at the
same time, and each Investor will be investing its Pro Rata Percentage of the Total Equity Commitment concurrently with each other Investor’s investment. The “Pro Rata Percentage,” as to each Investor, means the percentage set
forth opposite such Investor’s name on Schedule A. The “Surplus Net Cash” shall mean the amount, if any, by which the Net Cash (as defined in the Merger Agreement) exceeds $38,000,000. 

 The Investors’ obligation to fund its Pro Rata Percentage of the Total Equity Commitment is
subject to (x) the execution and delivery of the Merger Agreement, (y) the consummation of the Merger and (z) the terms of this letter agreement. Parent shall use the proceeds from the Investors’ commitment hereunder at its sole
discretion, as directed by Parent’s Board of Directors and without any limitation or condition whatsoever from the Investors. 
 Each
of the Investor’s equity commitment hereunder may not be assigned, except (a) each of the Investors’ may assign all or a portion of its obligations to fund its Pro Rata Percentage of the Total Equity Commitment to any other Investor,
any additional equity co-investor or to its affiliates or affiliated funds, or, with written consent of Parent and the Company, to any third party (without consideration therefor); provided, however that each Investor shall remain
severally liable for its Pro Rata Percentage of the Total Equity Commitment and (b) the Company may, in consultation with Parent, assign all or a portion of the obligation to purchase shares of Parent Common Stock pursuant to this letter
agreement to a third party, which shall not be deemed effective unless and until such third party executes and delivers the Equity Purchase Documents (as defined below) on the terms set forth in the sixth paragraph hereof, it being agreed that,
without the consent of Parent, the purchase price per share of Parent Common Stock paid by such assignee may not be less than the Parent Stipulated Value; provided, however, that such purchase price may be higher without the consent of Parent. 

This letter agreement shall be binding solely on, and inure solely to the benefit of, each of the undersigned and their respective successors
and permitted assigns, and nothing set forth in this letter agreement shall be construed to confer upon or give to any person other than each of the undersigned and their respective successors and permitted assigns any benefits, rights or remedies
under or by reason of, or any rights to enforce or cause the Company to enforce, the equity commitment or any provisions of this letter agreement. 

Each of the Investors hereby covenants to enter into a Securities Purchase Agreement with Parent, a Registration Rights Agreement with Parent,
and such other agreements as may be reasonably requested by Parent in connection therewith (the “Equity Purchase Documents”), which shall set forth (i) the terms on which such Investor (or its respective successor or permitted
assigns) shall purchase that number of the shares of the Company equal to (x) its Pro Rata Percentage, multiplied by (y) the Total Equity Commitment hereunder, and divided by (z) the Parent Stipulated Value, (ii) certain
registration rights with respect to such shares of common stock under the Securities Act of 1933, as amended (which shall include, without limitation, Parent’s obligation to (A) file a registration statement with respect to the resale of
the shares of the Parent Common Stock sold pursuant to this letter agreement with the SEC within 60 days after the closing date; (B) use its commercially reasonable best efforts to have the registration statement declared effective by the SEC
as soon as possible after the initial filing, and in any event no later than 120 days after the closing date; and (C) keep the registration statement effective until all registrable securities may be sold pursuant to Rule 144 under the
Securities Act of 1933, without the need for current public information or other restriction), and (iii) other customary terms and conditions, each of which shall be on terms reasonably consistent with similar agreements by public companies
similarly situated with Parent. Notwithstanding anything to the contrary herein, the Investors understand and agree that the Equity Purchase Documents shall provide for: (a) the sale of Parent Common Stock and no other equity instrument at a
price equal to the Parent Stipulated Value (except as otherwise contemplated by 

  
 2 

 
subpart (b) of the fourth paragraph hereof); (b) the issuance of the Parent Common Stock as a private placement exempt from registration under Section 4(2) and Regulation D under
the Securities Act of 1933, as amended, and the rules promulgated thereunder, and that such exemption shall rely, in part, on the representations and warranties of the Investors included in the Equity Purchase Documents; (c) the closing of the
sale of the Parent Common Stock occurring immediately following the closing of the Merger; and (d) no representations and warranties of Parent other than fundamental representations and warranties (including with respect to capitalization and
SEC filings). 
 The parties hereto agree that irreparable damage would occur if any provision of this Letter Agreement were not performed
in accordance with the terms hereof and that the Company or the Investors, as the case may be, shall be entitled to an injunction or injunctions to prevent breaches of this letter agreement or to enforce specifically the performance of the terms and
provisions hereof in any federal court located in the State of Delaware or any Delaware state court, in addition to any other remedy to which they are entitled at law or in equity. The parties hereto hereby agree not to raise any objections to the
equitable remedy of specific performance to prevent or restrain breaches or threatened breaches of this Letter Agreement, and to specifically enforce the terms and provisions of this Agreement to prevent breaches or threatened breaches of, or to
enforce compliance with, the covenants and obligations of the Investors under this letter agreement. 
 In the event that any suit or action
is instituted with respect to this letter agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all reasonable fees, costs and expenses of such prevailing party in connection with any such suit or action,
including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all reasonable fees, costs and expenses of appeals. 

This letter agreement may be executed in counterparts. This letter agreement and any related dispute shall be governed by, and construed and
interpreted in accordance with, the laws of the State of Delaware applicable to contracts executed in and to be performed in that State. Each of the parties hereto hereby (a) irrevocably submit to the personal jurisdiction of the Delaware Court
of Chancery and any state appellate court therefrom within the State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any state or federal court within the State of Delaware) in the event
that any dispute arises out of this letter agreement or any of the transactions contemplated by this letter agreement, (b) agree that it will not attempt to deny or defeat such personal jurisdiction or venue by motion or other request for leave
from any such court and (c) agree that it will not bring any action relating to this letter agreement or any of the transactions contemplated by this letter agreement in any court other than the Delaware Court of Chancery and any state
appellate court therefrom within the State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any state or federal court within the State of Delaware). 

Each of the Investors represents and warrants that: (i) it has the requisite power, capacity and authority to execute and deliver this
letter agreement and to fulfill and perform its obligations hereunder; (ii) this letter agreement has been duly and validly executed and delivered by the Investor and constitutes a legal, valid and binding agreement of the Investor and is
enforceable in accordance with its terms (subject to the effects of bankruptcy, insolvency, 

  
 3 

 
fraudulent conveyance, reorganization, moratorium or other similar laws affecting creditors’ rights generally and general equitable principles whether considered in a proceeding in law or in
equity); (iii) the execution, delivery and performance of this letter agreement by the Investor has been duly and validly authorized and approved by all necessary corporate, limited partnership or similar action by such party; (iv) the
Investor has available, unrestricted cash (or the unrestricted right (subject only to the giving of any required notices) to obtain from its investors the funds necessary) sufficient to pay and perform in full its obligations under this letter
agreement; (v) all funds necessary for the Investor to fulfill its obligations under this letter agreement shall be available to the Investor for so long as this letter agreement shall remain in effect; (vi) the Investor has received and
reviewed (or has had sufficient opportunity to review) the Merger Agreement and this letter agreement with independent legal, accounting and financial advisors regarding the Investor’s rights and obligations and the Investor fully understands
the terms and conditions contained, and the transactions provided for, herein and therein; and (vii) the Investor understands that the issuance of the shares of Parent Common Stock pursuant to the Equity Purchase Documents will be a private
placement exempt from registration under Section 4(2) and Regulation D under the Securities Act of 1933, as amended, and the rules promulgated thereunder (the “Securities Act”), and that such exemption shall rely, in part, on
the representations and warranties of the Investors included in the paragraph below and the Equity Purchase Documents. 
 Each Investor
understands that the shares of Parent Common Stock issued pursuant to the Equity Purchase Documents will be “restricted securities” and will not, at the time of issuance, have been registered under the Securities Act or any applicable
state securities law and is acquiring such shares as principal for its own account and not with a view to, or for distributing or reselling such shares or any part thereof in violation of the Securities Act or any applicable state securities laws,
provided, however, that by making the representations herein, such Investor does not agree to hold any of the Shares for any minimum period of time and reserves the right, subject to the provisions of the Equity Purchase Documents and any
lock-up agreement executed in connection with the Merger Agreement, at all times to sell or otherwise dispose of all or any part of such shares pursuant to an effective registration statement under the Securities Act or under an exemption from such
registration and in compliance with applicable federal and state securities laws. Such Investor will acquire the shares thereunder in the ordinary course of its business. Such Investor does not presently have any agreement, plan or understanding,
directly or indirectly, with any Person to distribute or effect any distribution of any of the shares (or any securities which are derivatives thereof) to or through any person or entity; such Investor is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business that would require it to be so registered as a broker-dealer. Such Investor is, at
the date hereof, an “accredited investor” as defined in Rule 501(a) under the Securities Act. Such Investor will not be purchasing the shares as a result of any advertisement, article, notice or other communication regarding the shares
published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general advertisement. Such Investor, either alone or together with its representatives, has such knowledge,
sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the shares, and has so evaluated the merits and risks of such investment. Such Investor is able
to bear the economic risk of an investment in the shares and, at the present time, is able to afford a complete loss of such investment. Such Investor acknowledges that it has reviewed publicly available materials

  
 4 

 
relating to the Company and Parent and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company
and Parent concerning the terms and conditions of the offering of the shares and the merits and risks of investing in the shares; (ii) access to information about the Company, Parent and their subsidiaries and their respective financial
condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company and Parent possess or can
acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Such Investor has sought such accounting, legal and tax advice as it has considered necessary to make an
informed decision with respect to its commitment to acquire the shares. 
 Parent may, on or after the date hereof, issue a press release
disclosing the material terms of the transactions contemplated by this letter agreement and may, on or after the date hereof file a Current Report on Form 8-K describing the terms of this letter agreement and including the press release and a copy
of this letter agreement, as exhibits thereto, with the Securities and Exchange Commission. 
 EACH OF THE PARTIES HERETO HEREBY WAIVES TO
THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS LETTER AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED
HEREBY. 
 This letter agreement may not be amended or otherwise modified without the prior written consent of Parent, the Company and each
of the undersigned. 
 This letter agreement shall expire upon the termination of the Merger Agreement in accordance with its terms. Nothing
in this paragraph shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this letter agreement or the Merger Agreement or other agreements delivered in connection therewith or to impair
the right of any party to compel specific performance by any other party of its obligations under this letter agreement, the Merger Agreement or such other agreements. 

[REMAINDER OF PAGE LEFT BLANK INTENTIONALLY] 

  
 5 

 Sincerely, 

 

			
	CANAAN VII LLC
	By:	 	Canaan Partners VII LLC
	By:	 	/s/_Brent Ahrens
	Name:	 	Brent Ahrens
	Title:	 	Member/ Manager
	
	DOMAIN PARTNERS VII, L.P.
	By:	 	One Palmer Square Associates VII, L.L.C.
	Its:	 	General Partner
	By:	 	/s/ Lisa A. Kraeutler
		 	Lisa A. Kraeutler
		 	Attorney-in-fact
	
	DP VII ASSOCIATES, L.P.
	By:	 	One Palmer Square Associates VII, L.L.C.
	Its:	 	General Partner
	By:	 	/s/ Lisa A. Kraeutler
		 	Lisa A. Kraeutler
		 	Attorney-in-fact
	
	DOMAIN ASSOCIATES, LLC
	By:	 	/s/ Kathleen K. Shoemaker
		 	Kathleen K. Shoemaker
		 	Managing Member
	
	FRAZIER HEALTHCARE V, L.P.
	By FHM V, LP, its general partner
	By FHM V, LLC, its general partner
	By:	 	/s/ Patrick Heron
		 	Patrick Heron, Manager
	
	MONTREUX EQUITY PARTNERS IV, LP
	By:	 	Montreux Equity Partners IV, LLC, its General Partner
	By:	 	/s/ Daniel K. Turner III
		 	Daniel K. Turner III, Managing Member
	
	MONTREUX IV ASSOCIATES, LLC
	By:	 	Montreux Equity Partners IV, LLC, its General Partner
	By:	 	/s/ Daniel K. Turner III
		 	Daniel K. Turner III, Managing Member
	
	MONTREUX EQUITY PARTNERS V, LP
	By:	 	 Montreux Equity Partners V, LLC, its
 General
Partner

	By:	 	/s/ Daniel K. Turner III
		 	Daniel K. Turner III, Managing Member
	
	NOVO A/S
	By:	 	Jack Nielsen
	Its:	 	Partner
	By:	 	/s/ Jack Nielsen

 [Signature page to Equity Commitment Letter] 

  
 6 

 Accepted and Agreed to as of the date first above written. 

 

					
	REGADO BIOSCIENCES, INC.
		
	By:	 	/s/ Michael A. Metzger
			
		 	Name:	 	Michael A. Metzger
		 	Title:	 	Chief Executive Officer, President and Chief Operating Officer
	
	TOBIRA THERAPEUTICS, INC.
		
	By:	 	/s/ Laurent Fischer, M.D.
	Name:	 	Laurent Fischer, M.D.
	Title:	 	Chief Executive Officer

 [Signature page to Equity Commitment Letter] 

  
 7 

  

Schedule A 
 List of Investors 

 

							
	 Investor
	  	Pro Rata Percentage	 	Maximum
Investment	 
	 Funds affiliated with Novo A/S
	  	50.53%	 	$	11,116,600.00	  
	 Funds affiliated with Domain Associates, L.L.C.
	  	21.05%	 	$	4,631,000.00	  
	 Funds affiliated with Frazier Healthcare V, L.P.
	  	12.63%	 	$	2,778,600.00	  
	 Funds affiliated with Canaan VII L.P.
	  	8.42%	 	$	1,852,400.00	  
	 Funds affiliated with Montreux Equity Partners IV, LP
	  	7.37%	 	$	1,621,400.00	  

  
 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]